In particular, Ali et al. demonstrated, in induced EGFR mutated TKI-resistant NSCLC cell lines, a major tumor growth inhibition and reduction in cholesterol levels with the concomitant use of atorvastatin and gefitinib [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.